Dr. William Williams reports

"ELEVEN CLINICAL TRIALS THAT WILL SHAPE MEDICINE IN 2026" – BRIACELL PHASE 3 TRIAL FEATURED IN NATURE MEDICINE

Briacell Therapeutics Corp.'s phase 3 Bria-IMT clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review's publication, "Eleven clinical trials that will shape medicine in 2026."

• Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID;
• Briacell's phase 3 clinical trial in metastatic breast cancer featured as "clinical trial to watch in 2026;"
• Briacell anticipates reporting top-line data as early as H1 (first half) 2026.

As quoted in the Nature Medicine feature, Dr. Sara A. Hurvitz, MD, FACP, stated: "The BRIA-ABC trial is an exciting study focused on people living with metastatic breast cancer. Even though cancer care has come a long way, metastatic breast cancer is still rarely curable and only a small fraction of patients benefit long-term from current immunotherapy or targeted treatments. That is why this trial was designed -- to see if a new cell-based immunotherapy, called Bria-IMT, can actually improve outcomes for people who have already gone through many prior treatments."

"What really sets BRIA-ABC apart is how inclusive it is. It welcomes individuals with all breast cancer subtypes, including patients who cannot work but are able to take care of themselves -- and those with brain metastases and people who have already had extensive prior treatments, even antibody-drug conjugates or checkpoint inhibitors. Plus, it uses a real-world comparator arm, making the results much more meaningful for everyday clinical practice." Dr. Sara A. Hurvitz holds the Smith Family Endowed Chair in Women's Health at the Fred Hutchinson Cancer Center, Seattle, Wash., United States.

Briacell anticipates reporting top-line data as early as H1 2026.

Briacell's pivotal phase 3 clinical study is evaluating Briacell's lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician's choice in advanced metastatic breast cancer (Bria-ABC).

Briacell recently reported its phase 3 clinical study has screened more than 230 patients and enrolled over 160 patients to date. Interim data will be analyzed once 144 patient events (deaths) occur. This interim analysis will evaluate overall survival (OS) as the primary end point, comparing patients treated with the Bria-IMT combination regimen to those receiving physician's choice therapy. Positive results from this pivotal study could support full approval and marketing authorization of Bria-IMT for patients with metastatic breast cancer. The Bria-IMT combination regimen has been granted FDA fast-track designation.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.